From: Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
Author (year) | Sample size | WHO grade | Assay | Material | Tissue samples | Antibody | Staining patterns | Cut-offa | Rate (%)b |
---|---|---|---|---|---|---|---|---|---|
Wintterle et al. (2003) | 10 | III + IV | IHC | Frozen sections | Full slides | 5H1 | NM | Presence of PD-L1 staining | 100 |
Wilmotte et al. (2005) | 54 | II–IV | IHC | Frozen sections | Full slides | MIH1 | Membranous/cytoplasm | Presence of PD-L1 staining | 85.2 |
Yao et al. (2009) | 48 | I–IV | IHC | Frozen sections | Full slides | MIH1 (Ebioscience) | Membranous/cytoplasm | NM | NM |
I–IV | WB | Fresh tissues | Full slides | Anti-PD-L1 (R&D Systems) | NM | NM | 75.0 | ||
Avril et al. (2010) | 20 | IV | IHC | PE | NM | Anti-PD-L1 (Clinisciences) | NM | >25% | 45.0 |
Liu et al. (2013) | 17 | III + IV | IFC | Frozen sections | NM | Anti-human PD-L1 (558065; BD PharMingen) | NM | Presence of PD-L1 staining | 76.5 |
Berghoff et al. (2014) | 135 | IV | IHC | PE | Full slides | 5H1 | Membranous | >5% | 34.8 |
Diffuse/fibrillary | Presence of PD-L1 staining | 82.9 | |||||||
Nduom et al. (2015) | 99 | IV | IHC | PE | Tissue microarray | EPR1161(2) (Abcam) | Membranous | ≥1% | 60.6 |
Zeng et al. (2016) | 229 | I–IV | IHC | PE | Tissue microarrays | Rabbit anti-PD-L1 | Membranous/cytoplasm | >5% | 51.1 |
Garber et al. (2016) | 345 | I–IV | IHC | PE | Full slides | SP142 (Spring Biosciences) | Membrane | >5% | 6.1 |
Pooled data | 957 | Â | Â | Â | Â | Â | Â | Â | 44.7 |